established an immune score by detecting the number and density of CD3+ and CD8+ T cells in the tumor center and peritumoral area and predicted the prognosis of recurrence-free survival and OS of CRCLM patients, which was confirmed by internal validation. Here, CD8A is linked to neoplasm.